Access to the text (HTML) Access to the text (HTML)
PDF Access to the PDF text

Access to the full text of this article requires a subscription.
  • If you are a subscriber, please sign in 'My Account' at the top right of the screen.

  • If you want to subscribe to this journal, see our rates

  • You can purchase this item in Pay Per ViewPay per View - FAQ : 30,00 € Taxes included to order
    Pages Iconography Videos Other
    4 0 0 0

Joint Bone Spine
Volume 71, n° 4
pages 257-260 (juillet 2004)
Doi : 10.1016/j.jbspin.2004.01.002
Received : 24 October 2003 ;  accepted : 8 January 2004
Is dosage reduction appropriate in patients who respond well to anti-TNF-alpha agents?

Jean-Marie  Berthelot * ,  Stéphane  Varin
Rheumatology Department, Hôtel-Dieu CHU Nantes, 44093, Nantes cedex 01, France 

*Corresponding author.

Mots clés  : Anti-TNF alpha ; Infliximab ; Etanercept ; Adalimumab ; Cost ; Dosage.

© 2004  Elsevier SAS. All Rights Reserved.

EM-CONSULTE.COM is registrered at the CNIL, déclaration n° 1286925.
As per the Law relating to information storage and personal integrity, you have the right to oppose (art 26 of that law), access (art 34 of that law) and rectify (art 36 of that law) your personal data. You may thus request that your data, should it be inaccurate, incomplete, unclear, outdated, not be used or stored, be corrected, clarified, updated or deleted.
Personal information regarding our website's visitors, including their identity, is confidential.
The owners of this website hereby guarantee to respect the legal confidentiality conditions, applicable in France, and not to disclose this data to third parties.
Article Outline